ACC partners with Amgen and Veradigm on TRANSFORM: ACS study

1313
Drawing blood for a cholesterol test

The American College of Cardiology (ACC) will collaborate with Amgen and Veradigm on a study to transform care for acute coronary syndrome (ACS) patients at risk for future cardiovascular events. TRANSFORM: Accelerating Lipid Lowering Post ACS (TRANSFORM: ACS) will ensure ACS patients quickly receive cholesterol testing in the hospital and guideline-recommended therapies to reduce LDL cholesterol in the hospital and upon discharge.

ACS is any condition that causes sudden reduced blood flow to the heart, including myocardial infarction (MI). It often causes severe chest pain or discomfort and must be diagnosed and treated quickly to improve blood flow and prevent future complications or problems.

Statins to reduce LDL, or bad, cholesterol are a cornerstone in the secondary prevention of cardiovascular events after an MI, and guidelines recommend that high-intensity statins be initiated in-hospital for ACS patients. However, LDL-C goals as recommended by ACC/AHA 2018 Guideline on the Management of Blood Cholesterol and ACC Non-Statin Expert Consensus Decision Pathway, are frequently not attained.

“Research has noted gaps in optimal care delivery for ACS patients. Our collaborative study will investigate mechanisms for early initiation, and test pilots for close follow-up, of lipid lowering therapies,” said ACC president Athena Poppas. “ACC is mission driven to transform cardiovascular care for all patients, and this novel approach should reduce the risk of recurrent major adverse events.”

The primary goal of the TRANSFORM: ACS programme will be to improve the rate of lipid panel testing and lipid lowering treatment intensification in ACS patients within 75 days after hospital discharge. Rapid cholesterol testing after a cardiovascular event within the hospital is hypothesised to drive initiation of lipid lowering treatment within the first-year post ACS, which could increase compliance and help patients avoid events more rapidly than current standard of care.

“LDL-C is one of the most important modifiable risk factors in reducing the risk of another cardiovascular event and studies have shown that many people who are at very high-risk, including those with ACS, are not being treated to the ACC/AHA guidelines and more intensive efforts are needed,” said Cesar Cerezo Olmos, vice president of Global and US Medical for Amgen’s General Medicine business unit. “Supporting TRANSFORM: ACS represents our commitment to helping patients with cardiovascular disease improve outcomes, as well as our proactive approach to care designed to predict and help prevent another potentially life-altering CV event from happening.”

The project will have two phases. Phase one will focus on supporting in-hospital lipid lowering treatment of post-ACS patients as recommended. Phase two of the program will evaluate quality improvement by following discharged ACS patients into the outpatient care setting to evaluate trends in treatment and risk prevention for up to a year post-discharge.

“Veradigm is thrilled to participate in this innovative program with the ACC and Amgen, focused on optimising the care for ACS patients as they transition across care settings” said Tom Langan, CEO of Veradigm.  “By leveraging national inpatient and outpatient cardiovascular registries, this study has the potential to improve health outcomes by helping patients to achieve target LDL-C levels and thus significantly lowering their risk of future cardiac events.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here